Please note: This website includes an accessibility system. Press Control-F11 to adjust the website to the visually impaired who are using a screen reader; Press Control-F10 to open an accessibility menu.

Homepage
Tags search
BioProtect

CTech 24/7

BioProtect

3 stories about BioProtect

Is it time to reconsider PSA tests for Prostate Cancer?
01.09.22|Itay Barnea“The treating physician should determine what is best for the patient based on his unique age, family history, health, lifestyle, race, ethnic background, and other factors,” writes Itay Barnea, CEO of BioProtect
Which Israeli cancer treatment company raised $57 million and who is making money off double chins?
22.09.20|CTechCTech Daily Roundup: Medtronic invests $4.5 million as part of BioProtect $25 million series D
Medtronic invests $4.5 million as part of BioProtect $25 million series D
22.09.20|Meir OrbachProceeds of the round will finance the ongoing multicenter FDA clinical trial of BioProtect's lead product, the ProSpace balloon spacer, which protects prostate cancer patients undergoing radiation therapy

Twitter

Facebook

Rss

About CTech Terms of Use Privacy Policy

CTech 24/7

BioProtect

Is it time to reconsider PSA tests for Prostate Cancer?

Which Israeli cancer treatment company raised $57 million and who is making money off double chins?

Medtronic invests $4.5 million as part of BioProtect $25 million series D